Research report
Non-suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmitters

https://doi.org/10.1016/j.jad.2009.10.028Get rights and content

Abstract

Background

Self-inflicted injury, including cutting or burning, is the most frequent reason for psychiatric visits to medical emergency departments. This behavior, particularly when there is no apparent suicidal intent, is poorly understood from both biological and clinical perspectives.

Objective

To examine the role of endogenous opioids and monoamine neurotransmitters in non-suicidal self-injury (NSSI).

Methods

We compared cerebrospinal fluid (CSF) levels of endogenous opioids, 5 hydroxyindolacetic acid (5-HIAA) and homovanillic acid (HVA) in individuals with a history of repetitive non-suicidal self-injury with a diagnostically-matched group of individuals who had never engaged in non-suicidal self-injury. History of suicidal behavior, demographic background and psychopathology was assessed. All patients were diagnosed with a Cluster B personality disorder (i.e. borderline, antisocial, narcissistic or histrionic) (N = 29) and had a history of at least one suicide attempt. Fourteen participants had a history of repeated non-suicidal self-injurious behavior (NSSI) in adulthood and 15 did not (no NSSI).

Results

The NSSI group had significantly lower levels of CSF β-endorphin and met-enkephalin when compared with the non-NSSI group. CSF dynorphin, HVA and 5-HIAA levels did not differ. Severity of depression, hopelessness and overall psychopathology was greater in the NSSI group.

Conclusion

β-endorphin and met-enkephalin, opioids acting upon receptors involved in mediating stress-induced and physical pain analgesia respectively, are implicated in NSSI. Serotonergic and dopaminergic dysfunctions do not appear to be related to NSSI. Based on our findings, we propose a model of non-suicidal self-injury. Our results suggest that drugs acting on the opioid system warrant exploration as pharmacological treatments for NSSI.

Introduction

Non-suicidal self-injury (NSSI), defined as self-injurious behavior without the intent to die, is a puzzling and poorly understood phenomenon. NSSI usually begins in adolescence, and most commonly takes the form of cutting, burning, or self-hitting (Nock and Favazza, 2007). The behavior often becomes habitual, persists into adulthood (Stanley et al., 1992, Simeon and Hollander, 2001, Nada-Raja et al., 2004) and is often treatment refractory (Perry et al., 2009). Individuals who exhibit NSSI are at increased risk for suicidal behavior (Stanley and Brodsky, 2005, Hawton and Harriss, 2006, Hawton and Harriss, 2007) with many self-injurers having a history of multiple suicide attempts (Nock et al., 2006). Self-injurers often report a compulsive quality to their behavior, typically associated with a need to relieve tension, or alleviate emotional distress or pain (Klonsky, 2007). Some reports suggest disturbances in reward circuity or pain regulation in individuals who self-injure (Kemperman, 1997, Schmahl et al., 2004), while others have associated NSSI with emotion-focused and avoidance-focused coping styles (Williams and Hasking, 2009). NSSI occurs most often in individuals diagnosed with borderline personality disorder, a disorder characterized by self-destructive behavior, impulsivity and emotional lability (APA, 1994). However, several other disorders and syndromes have been associated with this behavior, including major depression (Langbehn and Pfohl, 1993), antisocial personality disorder (Isometsa et al., 1996), dissociative identity disorder (Saxe et al., 2002), posttraumatic stress disorder (Herman, 1992), eating disorders (Paul et al., 2002), autism (Nagamitsu et al., 1997), developmental disabilities (Nagamitsu, 1993) and Lesch–Nyhan syndrome (Anderson and Ernst, 1994).

While serotonergic and dopaminergic dysfunctions have been associated with suicidal behavior (van Heeringen, 2003, Mann and Currier, 2007), several converging lines of evidence suggest that the endogenous opioid system may play a more prominent role in self-injury where there is no suicidal intent (Stanley and Siever, 2010). There is a well-established relationship between pain perception and endogenous opioids (Urban and Gebhart, 1999, Fields, 2004, Przewlocki and Przewlocka, 2001). β-endorphin and met-enkephalin, which are primarily mu- and delta-receptor agonists respectively, play a role in antinociception broadly, and are involved in a phenomenon known as stress-induced analgesia (Rubinstein et al., 1996, Yamada and Nabeshima, 1995). Dynorphin, which binds primarily to the kappa opioid receptor, has a more complex role in the pain system, and has been found to be involved not only in analgesic states (Stevens and Yaksh, 1986), but also in stress-induced hyperalgesia (Vanderah et al., 2000) and the perpetuation of neuropathic pain (Lai et al., 2006). Research has demonstrated increased pain tolerance in individuals who self-injure (Claes et al., 2006) and in patients with borderline personality disorder (Ludascher et al., 2007). Also, regional activation of mu-opioid neurotransmission has been implicated in the suppression of the affective qualities of a pain stressor and in the negative internal affective states induced in a pain challenge paradigm. Zubieta et al., 2001, Zubieta et al., 2003 found dynamic changes in mu-opioid neurotransmission in response to an experimentally-induced negative affective state. Finally, β-endorphin plays an important role in the hypothalamic-pituitary adrenal stress response system via its role as a neuromodulator of corticotrophin-releasing hormone (Williams et al., 2003). There is also some evidence that the HPA axis is dysfunctional in individuals with BPD (Carrasco et al., 2007) and in individuals with a history of NSSI (Powers and McArdle, 2003).

Few studies have directly examined endogenous opioid levels in self-injurious behavior. Coid et al. (1983) found plasma levels of met-enkephalin to be associated with the recency and severity of NSSI in habitual self-injurers with BPD, while reduced baseline (Weizman et al., 1988) but elevated post-NSSI (Sandman, 2009) plasma β-endorphin levels have been found in individuals with developmental disorders. Although these findings are suggestive of a relationship between the opioid system and NSSI, plasma neuropeptide levels may not accurately reflect central levels. Several studies have found no substantial correlation between plasma and CSF β-endorphin in humans (Nakao et al., 1980, Tsigos et al., 1993, Geracioti et al., 1993, De Riu et al., 1997). Research investigating central opioid functioning is therefore necessary if we are to understand their role in NSSI.

While the CSF concentration of endogenous opioids (β-endorphin, met-enkephalin and dynorphin) in individuals with a history of self-injury has not been examined, lower levels of endogenous opioids have been implicated in the psychiatric disorders in which a self-destructive component exists. For example, Gillberg et al. (1990) found reduced levels of CSF β-endorphin in individuals with autism. In addition, Brewerton et al. (1992) reported that CSF β-endorphin levels were lower in individuals with bulimia nervosa than in healthy controls, while Demitrack et al. (1993) found a decrease in CSF β-endorphin levels in underweight anorexic individuals. In contrast, both Brewerton et al. and Lesem et al. (1991) found no difference in CSF dynorphin concentrations between individuals with eating disorders and normal controls. Taken together, the evidence suggests that dysregulation of the endogenous opioid system, and the mu-opioid system in particular, could underlie NSSI.

There is limited research examining the relationship between monoamine function and NSSI. Although serotonergic dysfunction is hypothesized to underlie self-injurious behavior associated with Prader–Willi Syndrome (Hellings and Warnock, 1994, Kishore and Stamm, 2006) and dopamine is implicated in Lesch–Nyhan disease (Allen and Rice, 1996, Wong et al., 1996), both genetic disorders characterized by self-injury, the findings in psychiatric samples with NSSI have been mixed. In a study comparing adolescent girls with a history of NSSI and age-matched controls, Crowell et al. (2005) found lower peripheral serotonin levels in girls with a history of NSSI. However, as with the neuropeptides, peripheral measures are not strong indicators of central monoamine function (Sarrias et al., 1990). Using CSF measures, Gardner et al. (1990) found no difference between BPD individuals with NSSI and without NSSI in CSF levels of 5-HIAA and HVA.

In this study, we examine three endogenous opioids: β-endorphin; met-enkephalin; and dynorphin in depressed individuals with Cluster B personality disorders and a history of suicidal behavior. We hypothesized that CSF β-endorphin and met-enkephalin levels, but not dynorphin level, would be reduced in depressed individuals with a history of NSSI. Because dynorphin appears to be primarily involved in the induction and maintenance of dysphoric states and neuropathic pain, we did not anticipate dynorphin levels to be associated with NSSI. In addition, we also examined the CSF levels of the monoamine metabolites 5-hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA). We hypothesized that serotonergic and dopaminergic dysfunctions would not be altered in these individuals because we propose that these dysfunctions, while related to self-injurious behavior with suicidal intent, would not be related to self-injurious behavior in which the intent is primarily to regulate emotional state and reduce tension.

Section snippets

Participants

Twenty-nine psychiatric patients at two large urban medical centers participated in the study after giving their written informed consent. The Institutional Review Boards approved the study which was part of a larger protocol investigating multiple clinical and biological aspects of NSSI and suicidal behavior. Inclusion criteria were: age 18–65 and DSM-IV (APA, 1994) Axis II diagnosis of a Cluster B personality disorder (i.e., borderline, antisocial, narcissistic, or histrionic). Exclusion

Results

The NSSI and no NSSI groups did not differ with respect to background characteristics. Age, sex, ethnicity, marital status, religious affiliation, education level, or employment rate did not differ between the groups (Table 1). All subjects were diagnosed with Cluster B personality disorder, all had BPD except one member of the NSSI group (histrionic) and two members of the no NSSI group (1 antisocial, 1 narcissistic). The rate of current major depression (about two thirds) did not differ

Discussion

This study is the first to report altered levels of CSF endogenous opioids in psychiatric patients with history of non-suicidal self-injury. We found that patients in the NSSI group had lower CSF levels of β-endorphin and met-enkephalin than a matched group of patients without NSSI but no difference in dynorphin levels between the two groups. We also found that, while serotonergic and dopaminergic dysfunctions have been reported in individuals with suicidal behavior (Mann and Currier, 2007),

Role of funding source

Funding for this study was provided by NIMH Grants # MH41847 and MH46745. The NIMH had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Conflict of interest

The authors of this manuscript have no financial or other relationships that are relevant to the subject matter of this research or the results described herein.

Acknowledgements

This study was supported in part by NIMH grants # MH41847 and MH46745 to Dr. Stanley.

References (93)

  • C. Gillberg et al.

    CSF β-endorphins in childhood neuropsychiatric disorders

    Brain Dev.

    (1990)
  • R. Gross-Isseroff et al.

    Regionally selective increases in mu opioid receptor density in the brains of suicide victims

    Brain Res.

    (1990)
  • K. Heffernan et al.

    Childhood trauma as a correlate of lifetime opiate use in psychiatric patients

    Addict. Behav.

    (2000)
  • T.R. Insel et al.

    Prenatal stress has long-term effects on brain opiate receptors

    Brain Res.

    (1990)
  • I. Kemperman

    Pain assessment in self-injurious patients with borderline personality disorder using signal detection theory

    Psychiatry Res.

    (1997)
  • M.D. Lesem et al.

    Measurement of CSF dynorphin A 1–8 immunoreactivity in anorexia nervosa and normal-weight bulimia

    Biol. Psychiatry

    (1991)
  • P. Ludascher et al.

    Elevated pain thresholds correlate with dissociation and aversive arousal in patients with borderline personality disorder

    Psychiatry Res.

    (2007)
  • M. Nock et al.

    Non-suicidal self-injury among adolescents: diagnostic correlates and relation to suicide attempts

    Psychiatry Res.

    (2006)
  • R. Przewlocki et al.

    Opioids in chronic pain

    Eur. J. Pharmacol.

    (2001)
  • G.L. Quirarte et al.

    Norepinephrine release in the amygdala in response to footshock and opioid peptidergic drugs

    Brain Res.

    (1998)
  • J. Roggenbach et al.

    Suicidality, impulsivity and aggression: Is there a link to 5HIAA concentration in the cerebrospinal fluid?

    Psychiatry Res.

    (2002)
  • M.D. Sanchez et al.

    Prenatal stress alters the hypothalamic levels of methionine-enkephalin in pup rats

    Neuropeptides

    (1992)
  • M.D. Sanchez et al.

    Autoradiographic evidence of mu-opioid receptors down-regulation after prenatal stress in offspring rat brain

    Brain Res. Dev. Brain Res.

    (1996)
  • C.A. Sandman et al.

    Naloxone attenuates self-abusive behavior in developmentally disabled clients

    Appl. Res. Ment. Retard.

    (1983)
  • C. Schmahl et al.

    Differential nociceptive deficits in patients with borderline personality disorder and self-injurious behavior: laser-evoked potentials, spatial discrimination of noxious stimuli, and pain ratings

    Pain

    (2004)
  • L. Sher

    The endogenous euphoric reward system that reinforces physical training: a mechanism for mankind's survival

    Med. Hypotheses

    (1998)
  • M. Urban et al.

    Central mechanisms in pain

    Med. Clin. North Am.

    (1999)
  • S.H. van Goozen et al.

    Increased adrenal androgen functioning in children with oppositional defiant disorder: a comparison with psychiatric and normal controls

    J. Am. Acad. Child Adolesc. Psych.

    (2000)
  • R. Weizman et al.

    Low plasma immunoreactive β-endorphin levels in autism

    J. Am. Acad. Child Adolesc. Psych.

    (1988)
  • K.L. Williams et al.

    Effect of opioid receptor antagonists on hypothalamic-pituitary-adrenal activity in rhesus monkeys

    Psychoneuroendocrinology

    (2003)
  • K. Yamada et al.

    Stress-induced behavioral responses and multiple opioid systems in the brain

    Behav. Brain Res.

    (1995)
  • H. Akil et al.

    Endogenous opioids: biology and function

    Annu. Rev. Neurosci.

    (1984)
  • American Psychiatric Association

    Diagnostic and Statistical Manual of Mental Disorders

    (1994)
  • L.T. Anderson et al.

    Self-injury in Lesch–Nyhan disease

    J. Autism Dev. Disord.

    (1994)
  • M. Baron

    The Schedule for Interviewing Borderlines

    (1980)
  • A.T. Beck et al.

    An inventory for measuring depression

    Arch. Gen. Psychiatry

    (1965)
  • T.D. Brewerton et al.

    CSF β-endorphin and dynorphin in bulimia nervosa

    Am. J. Psychiatry

    (1992)
  • A.H. Buss et al.

    An inventory for assessing different kinds of hostility

    J. Consult. Psychol.

    (1957)
  • A. Bystritsky et al.

    Treatment of obsessive–compulsive cutting behavior with naltrexone

    J. Clin. Psychiatry

    (1996)
  • J.L. Carrasco et al.

    Hypothalamic-pituitary-adrenal axis response in borderline personality disorder without post-traumatic features

    Br. J. Psychiatry

    (2007)
  • J.A. Casner et al.

    Naltrexone and self-injurious behavior: a retrospective population study

    J. Clin. Psychopharmacol.

    (1996)
  • N. Chabane et al.

    Opiate antagonists in children and adolescents

    Eur. Child Adolesc. Psychiatry

    (2000)
  • S.E. Crowell et al.

    Psychological, autonomic, and serotonergic correlates of parasuicide among adolescent girls

    Dev. Psychopathol.

    (2005)
  • H. Fields

    State-dependent opioid control of pain

    Nat. Rev. Neurosci.

    (2004)
  • A.J. Good et al.

    Effects of a microinjection of morphine into the amygdala on the acquisition and expression of conditioned fear and hypoalgesia in rats

    Behav. Neurosci.

    (1995)
  • K.L. Gratz

    Risk factors for and functions of deliberate self-harm: an empirical and conceptual review

    Clin. Psychol. Sci. Pract.

    (2003)
  • Cited by (159)

    View all citing articles on Scopus
    View full text